Published in Law and Health Weekly, April 3rd, 2010
Proceeds from the Series C financing will enable Promedior to accelerate the development of its pipeline and expand the clinical development program for its lead drug candidate, PRM-151, into Phase 2...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly